Stephen J Kent
Overview
Explore the profile of Stephen J Kent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
363
Citations
12367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burmas L, Lee W, Kelly A, Webster R, Esterbauer R, Kent S, et al.
J Immunol
. 2025 Mar;
PMID: 40073085
Human clinical trials have reported immunological outcomes can differ between ipsilateral (same side) and contralateral (alternate sides) prime-boost vaccination. However, our mechanistic understanding of how keeping or shifting the anatomical...
2.
Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P, et al.
Sci Adv
. 2025 Feb;
11(9):eads1482.
PMID: 40009690
Repeated mRNA COVID-19 vaccination increases spike-specific immunoglobulin G4 (IgG4) titers. Here, we characterized the influence of increased IgG4 titers on a range of Fc-mediated responses. Elevated spike-specific IgG4 reduced binding...
3.
Lee W, Selva K, Audsley J, Kent H, Reynaldi A, Schlub T, et al.
JCI Insight
. 2025 Jan;
10(4).
PMID: 39786918
BACKGROUNDThe immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are...
4.
Pilapitiya D, Lee W, Vu M, Kelly A, Webster R, Koutsakos M, et al.
Vaccine
. 2024 Dec;
46():126668.
PMID: 39740385
Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal...
5.
Grobben M, Bakker M, Schriek A, Levels L, Umotoy J, Tejjani K, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012739.
PMID: 39661636
HIV-1 infection leads to chronic disease requiring life-long treatment and therefore alternative therapeutics, a cure and/or a protective vaccine are needed. Antibody-mediated effector functions could have a role in the...
6.
Larson E, Ellis A, Rodgers M, Gubernat A, Gleim J, Moriarty R, et al.
Infect Immun
. 2024 Oct;
92(12):e0031324.
PMID: 39475292
Children living with HIV have a higher risk of developing tuberculosis (TB), a disease caused by the bacterium (Mtb). Gamma delta (γδ) T cells in the context of HIV/Mtb coinfection...
7.
Ju Y, Li S, Tan A, Pilkington E, Brannon P, Plebanski M, et al.
ACS Nano
. 2024 Oct;
18(42):29021-29035.
PMID: 39380440
Antibody-directed targeting of chemotherapeutic nanoparticles to primary human cancers holds promise for improving efficacy and reducing off-target toxicity. However, clinical responses to targeted nanomedicines are highly variable. Herein, we prepared...
8.
Cromer D, Reynaldi A, Mitchell A, Schlub T, Juno J, Wheatley A, et al.
Nat Commun
. 2024 Sep;
15(1):8395.
PMID: 39333473
The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based largely on...
9.
Kent S, Li S, Amarasena T, Reynaldi A, Lee W, Leeming M, et al.
ACS Nano
. 2024 Sep;
18(39):27077-27089.
PMID: 39298422
Lipid nanoparticle mRNA vaccines are an exciting but emerging technology used in humans. There is limited understanding of the factors that influence their biodistribution and immunogenicity. Antibodies to poly(ethylene glycol)...
10.
Hassanel D, Pilkington E, Ju Y, Kent S, Pouton C, Truong N
Int J Pharm
. 2024 Sep;
665:124695.
PMID: 39288840
Lipid nanoparticles (LNPs) have emerged as promising carriers to efficiently transport mRNA into cells for protein translation, as seen with the mRNA vaccines used against COVID-19. However, they contain a...